Premium
Acetate alters purinergic enzyme and receptor levels in glial cultures
Author(s) -
BHATT DHAVAL,
ROSENBERGER THAD ALLEN
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb522
Subject(s) - purinergic receptor , apyrase , receptor , neuroglia , neuroinflammation , lipopolysaccharide , adenosine , purinergic signalling , chemistry , medicine , microglia , endocrinology , adenosine receptor , biochemistry , biology , inflammation , central nervous system , agonist
Acetate supplementation increases brain acetyl‐CoA and histone/non‐histone protein acetylation that attenuates neuroglia activation and pro‐inflammatory cytokine release in rat models of neuroinflammation and neuroborreliosis. Because adenosine (ADO) and ATP are known to modulate neuroglia activation, we postulate that an anti‐inflammatory effect of acetate may involve altering purinergic signaling. To begin to test this hypothesis, we quantified the effect of acetate on purinergic enzymes and receptors in BV‐2 microglial cell cultures treated with lipopolysaccharide (LPS). Cultures were treated with sodium chloride (NaCl), sodium acetate (NaAc), NaCl+LPS, and NaAc+LPS for 12, 24, and 48 hr. The level of enzymes involved in ADO formation [ecto‐5′‐nucleotidase (CD73), ecto‐apyrase (CD39)], removal [ADO deaminase (ADA), ADO kinase (AK)], and ADO receptors (A 1 and A 2A ) were measured using Western blot analysis. We found that at 48 hr, acetate prevented the LPS‐induced 2‐fold increase in CD73, AK, and A 2A receptor when compared to controls. Further, ADA and A 1 receptor levels were increased to 1.3‐ and 1.5‐fold with LPS which were reduced to 0.5‐ and 0.7‐fold below control levels with acetate. These results suggest that acetate supplementation and an increase in acetyl‐CoA metabolism may modulate purinergic signaling in BV‐2 microglia. This work was supported by a grant from NIH/NIGMS, P30GM103329.